• Profile

Epigenetic combination therapy could overcome treatment resistance in epithelioid sarcomas and rhabdoid tumours

MedicalXpress Breaking News-and-Events Feb 07, 2024

Epithelioid sarcoma, a rare aggressive cancer that usually strikes young adults, and rhabdoid tumors, which affect children, have long been difficult to treat. But the outlook for people with these subtypes of soft tissue sarcoma brightened in 2020 when the Food and Drug Administration approved a targeted therapy called tazemetostat (Tazverik) for certain patients.

Memorial Sloan Kettering Cancer Center (MSK) sarcoma expert Mrinal Gounder, MD, led the research study that resulted in tazemetostat's approval for people whose tumor contained a mutation (change) in a gene called SMARCB1. Unfortunately, tazemetostat has not worked in most people with the mutation, and some patients who initially respond develop resistance to the drug.

Now an MSK research team led by physician-scientist Alex Kentsis, MD, Ph.D., together with Dr. Gounder and colleagues, has identified mechanisms that activate resistance to tazemetostat in epithelioid sarcoma and rhabdoid tumors. Based on this discovery, the researchers have designed a combination therapy that overcomes the resistance in a lab setting.

The combination therapy uses an epigenetic treatment strategy, which aims at altering the expression of genes. Epigenetic therapies are a new class of drugs that focus on modifying the activity of genes without changing the underlying DNA sequence. In some cases, these therapies can reprogram cancer cells to turn them into normal cells.

"By understanding the mechanisms of resistance, we were able to develop a combination therapy strategy that could improve treatment of not just epithelioid sarcoma but many types of cancer with similar epigenetic defects," Dr. Kentsis says. The researchers report their findings in Cancer Discovery.

Mutation in SMARCB1 leads to overactive EZH2 protein

Epithelioid and rhabdoid sarcomas develop when SMARCB1 is mutated. The gene is a tumor suppressor, which helps regulate cell growth and keep it in check. Loss of SMARCB1 function causes a protein called EZH2 to become overactive, driving the cell to grow uncontrollably and become cancerous.

In people whose tumors respond to tazemetostat, the drug blocks EZH2 and is able to restore the normal expression of genes, including those that regulate cell growth. This reprograms the cancer cells so they behave like normal cells. But in most patients, blocking EZH2 alone is not enough. Either the drug has no effect, or it works for a short time and then the cancer begins to grow again.

To understand how resistance to tazemetostat develops, Dr. Kentsis and colleagues studied samples donated for research by MSK patients with epithelioid sarcomas or rhabdoid tumors. They analyzed tumors from 33 patients using MSK-IMPACT, a tumor-sequencing test that looks for mutations in more than 500 genes.

"It can be difficult to study rare cancers due to the challenge of getting enough tumors to generate answers," Dr. Kentsis says. "But we were able to take advantage of being at a research institution like MSK, where our patients generously donate their samples and participate in clinical trials."

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen